• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

嘌呤能信号在 COVID-19 中的可能作用。

Possible role of purinergic signaling in COVID-19.

机构信息

Medicine Course, Federal University of Fronteira Sul, Campus Chapecó, Chapecó, SC, Brazil.

Post-Graduation Program in Biological Sciences: Toxicological Biochemistry, CCNE, Federal University of Santa Maria, Santa Maria, RS, Brazil.

出版信息

Mol Cell Biochem. 2021 Aug;476(8):2891-2898. doi: 10.1007/s11010-021-04130-4. Epub 2021 Mar 19.

DOI:10.1007/s11010-021-04130-4
PMID:33740184
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7973800/
Abstract

The coronavirus disease (COVID-19), caused by SARS-CoV-2 infection, accounts for more than 2.4 million deaths worldwide, making it the main public health problem in 2020. Purinergic signaling is involved in the pathophysiology of several viral infections which makes the purinergic system a potential target of investigation in COVID-19. During viral infections, the ATP release initiates a cascade that activates purinergic receptors. This receptor activation enhances the secretion of pro-inflammatory cytokines and performs the chemotaxis of macrophages and neutrophils, generating an association between the immune and the purinergic systems. This review was designed to cover the possible functions of purinergic signaling in COVID-19, focusing on the possible role of purinergic receptors such as P2X7 which contributes to cytokine storm and inflammasome NLRP3 activation and P2Y1 that activates the blood coagulation pathway. The possible role of ectonucleotidases, such as CD39 and CD73, which have the function of dephosphorylating ATP in an immunosuppressive component, adenosine, are also covered in detail. Moreover, therapeutic combination or association possibilities targeting purinergic system components are also suggested as a possible useful tool to be tested in future researches, aiming to unveil a novel option to treat COVID-19 patients.

摘要

由 SARS-CoV-2 感染引起的冠状病毒病(COVID-19)在全球范围内导致超过 240 万人死亡,成为 2020 年的主要公共卫生问题。嘌呤能信号参与几种病毒感染的病理生理学,这使得嘌呤能系统成为 COVID-19 研究的潜在目标。在病毒感染期间,ATP 的释放引发了一系列级联反应,激活了嘌呤能受体。这种受体的激活增强了促炎细胞因子的分泌,并趋化巨噬细胞和中性粒细胞,从而使免疫和嘌呤能系统之间产生关联。本综述旨在涵盖嘌呤能信号在 COVID-19 中的可能作用,重点关注嘌呤能受体(如 P2X7)的可能作用,该受体有助于细胞因子风暴和炎症小体 NLRP3 的激活,以及 P2Y1 的作用,其激活了血液凝固途径。还详细介绍了核苷酸酶(如 CD39 和 CD73)的可能作用,它们具有将 ATP 去磷酸化为免疫抑制成分腺苷的功能。此外,还提出了针对嘌呤能系统成分的联合治疗或联合治疗的可能性,作为未来研究中可能有用的工具,旨在为 COVID-19 患者的治疗提供新的选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7aa/7973800/661a5ae87217/11010_2021_4130_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7aa/7973800/5976543461b0/11010_2021_4130_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7aa/7973800/bbbc8e320a6e/11010_2021_4130_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7aa/7973800/661a5ae87217/11010_2021_4130_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7aa/7973800/5976543461b0/11010_2021_4130_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7aa/7973800/bbbc8e320a6e/11010_2021_4130_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7aa/7973800/661a5ae87217/11010_2021_4130_Fig3_HTML.jpg

相似文献

1
Possible role of purinergic signaling in COVID-19.嘌呤能信号在 COVID-19 中的可能作用。
Mol Cell Biochem. 2021 Aug;476(8):2891-2898. doi: 10.1007/s11010-021-04130-4. Epub 2021 Mar 19.
2
Potential Therapeutic Role of Purinergic Receptors in Cardiovascular Disease Mediated by SARS-CoV-2.嘌呤能受体在 SARS-CoV-2 介导的心血管疾病中的潜在治疗作用。
J Immunol Res. 2020 Dec 1;2020:8632048. doi: 10.1155/2020/8632048. eCollection 2020.
3
Purinergic signaling: decoding its role in COVID-19 pathogenesis and promising treatment strategies.嘌呤能信号转导:解析其在 COVID-19 发病机制中的作用及有前景的治疗策略。
Inflammopharmacology. 2023 Dec;31(6):3005-3020. doi: 10.1007/s10787-023-01344-4. Epub 2023 Oct 8.
4
A Systematic Review of the Role of Purinergic Signalling Pathway in the Treatment of COVID-19.嘌呤能信号通路在治疗 COVID-19 中的作用的系统评价。
Int J Mol Sci. 2023 Apr 26;24(9):7865. doi: 10.3390/ijms24097865.
5
Purinergic receptor ligands: the cytokine storm attenuators, potential therapeutic agents for the treatment of COVID-19.嘌呤能受体配体:细胞因子风暴的抑制剂,治疗 COVID-19 的潜在治疗药物。
Immunopharmacol Immunotoxicol. 2021 Dec;43(6):633-643. doi: 10.1080/08923973.2021.1988102. Epub 2021 Oct 14.
6
A novel definition and treatment of hyperinflammation in COVID-19 based on purinergic signalling.基于嘌呤能信号转导的新型 COVID-19 过度炎症反应定义和治疗方法。
Purinergic Signal. 2022 Mar;18(1):13-59. doi: 10.1007/s11302-021-09814-6. Epub 2021 Nov 10.
7
Targeting purinergic receptors to suppress the cytokine storm induced by SARS-CoV-2 infection in pulmonary tissue.针对嘌呤能受体抑制 SARS-CoV-2 感染肺组织中细胞因子风暴。
Int Immunopharmacol. 2021 Nov;100:108150. doi: 10.1016/j.intimp.2021.108150. Epub 2021 Sep 13.
8
Defining the CD39/CD73 Axis in SARS-CoV-2 Infection: The CD73 Phenotype Identifies Polyfunctional Cytotoxic Lymphocytes.定义 SARS-CoV-2 感染中的 CD39/CD73 轴:CD73 表型鉴定多功能细胞毒性淋巴细胞。
Cells. 2020 Jul 22;9(8):1750. doi: 10.3390/cells9081750.
9
Purinergic signaling in liver disease.肝脏疾病中的嘌呤能信号传导
Dig Dis. 2014;32(5):516-24. doi: 10.1159/000360498. Epub 2014 Jul 14.
10
High levels of extracellular ATP lead to different inflammatory responses in COVID-19 patients according to the severity.高水平的细胞外 ATP 根据严重程度导致 COVID-19 患者产生不同的炎症反应。
J Mol Med (Berl). 2022 Apr;100(4):645-663. doi: 10.1007/s00109-022-02185-4. Epub 2022 Mar 6.

引用本文的文献

1
Adenosine deaminase mediates endothelial inflammation via an ADA1-CD26 interaction in post-COVID.在新冠康复后,腺苷脱氨酶通过ADA1-CD26相互作用介导内皮炎症。
Front Pharmacol. 2025 May 21;16:1578973. doi: 10.3389/fphar.2025.1578973. eCollection 2025.
2
Melatonin from Plants: Going Beyond Traditional Central Nervous System Targeting-A Comprehensive Review of Its Unusual Health Benefits.植物源褪黑素:超越传统的中枢神经系统靶向作用——对其非凡健康益处的全面综述
Biology (Basel). 2025 Jan 30;14(2):143. doi: 10.3390/biology14020143.
3
Receptors Involved in COVID-19-Related Anosmia: An Update on the Pathophysiology and the Mechanistic Aspects.

本文引用的文献

1
Evaluation of serum hepatic enzyme activities in different COVID-19 phenotypes.评价不同 COVID-19 表型的血清肝酶活性。
J Med Virol. 2021 Apr;93(4):2365-2373. doi: 10.1002/jmv.26729. Epub 2020 Dec 23.
2
Targeting adenosinergic pathway and adenosine A receptor signaling for the treatment of COVID-19: A hypothesis.靶向腺苷能通路和腺苷A受体信号传导治疗新型冠状病毒肺炎:一种假说。
Med Hypotheses. 2020 Nov;144:110012. doi: 10.1016/j.mehy.2020.110012. Epub 2020 Jun 19.
3
A systematic review of pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of disease progression.
与 COVID-19 相关的嗅觉丧失的受体:病理生理学和机制方面的最新进展。
Int J Mol Sci. 2024 Aug 5;25(15):8527. doi: 10.3390/ijms25158527.
4
Genetic Polymorphisms of P2RX7 but Not of ADORA2A Are Associated with the Severity of SARS-CoV-2 Infection.P2RX7 基因多态性而非 ADORA2A 与 SARS-CoV-2 感染的严重程度相关。
Int J Mol Sci. 2024 Jun 2;25(11):6135. doi: 10.3390/ijms25116135.
5
A Prospective Study Investigating Immune Checkpoint Molecule and CD39 Expression on Peripheral Blood Cells for the Prognostication of COVID-19 Severity and Mortality.一项前瞻性研究调查了外周血细胞中免疫检查点分子和 CD39 的表达,以预测 COVID-19 的严重程度和死亡率。
Viruses. 2024 May 20;16(5):810. doi: 10.3390/v16050810.
6
Purinergic signaling in the battlefield of viral infections.病毒感染战场中的嘌呤能信号传导
Purinergic Signal. 2025 Feb;21(1):83-98. doi: 10.1007/s11302-023-09981-8. Epub 2023 Dec 1.
7
The bumpy road of purinergic inhibitors to clinical application in immune-mediated diseases.嘌呤能抑制剂在免疫介导疾病中临床应用的坎坷之路。
Neural Regen Res. 2024 Jun 1;19(6):1206-1211. doi: 10.4103/1673-5374.386405. Epub 2023 Oct 2.
8
Potential biomarkers for fatal outcome prognosis in a cohort of hospitalized COVID-19 patients with pre-existing comorbidities.住院 COVID-19 合并基础疾病患者队列中预示死亡结局的潜在生物标志物。
Clin Transl Sci. 2023 Dec;16(12):2687-2699. doi: 10.1111/cts.13663. Epub 2023 Nov 9.
9
Purinergic signaling: decoding its role in COVID-19 pathogenesis and promising treatment strategies.嘌呤能信号转导:解析其在 COVID-19 发病机制中的作用及有前景的治疗策略。
Inflammopharmacology. 2023 Dec;31(6):3005-3020. doi: 10.1007/s10787-023-01344-4. Epub 2023 Oct 8.
10
A Systematic Review of the Role of Purinergic Signalling Pathway in the Treatment of COVID-19.嘌呤能信号通路在治疗 COVID-19 中的作用的系统评价。
Int J Mol Sci. 2023 Apr 26;24(9):7865. doi: 10.3390/ijms24097865.
对 COVID-19 病理学发现的系统回顾:疾病进展的病理生理学时间轴和可能机制。
Mod Pathol. 2020 Nov;33(11):2128-2138. doi: 10.1038/s41379-020-0603-3. Epub 2020 Jun 22.
4
Is COVID-19 associated thrombosis caused by overactivation of the complement cascade? A literature review.COVID-19 相关血栓是否由补体级联的过度激活引起?文献综述。
Thromb Res. 2020 Oct;194:36-41. doi: 10.1016/j.thromres.2020.06.027. Epub 2020 Jun 18.
5
COVID-19-associated coagulopathy: An exploration of mechanisms.COVID-19 相关凝血功能障碍:机制探索。
Vasc Med. 2020 Oct;25(5):471-478. doi: 10.1177/1358863X20932640. Epub 2020 Jun 19.
6
New (re)purpose for an old drug: purinergic modulation may extinguish the COVID-19 thromboinflammatory firestorm.新型(再)用途的老药:嘌呤能调节可能扑灭 COVID-19 的血栓炎症风暴。
JCI Insight. 2020 Jul 23;5(14):140971. doi: 10.1172/jci.insight.140971.
7
COVID-19: An Alert to Ventilator-Associated Bacterial Pneumonia.新型冠状病毒肺炎:对呼吸机相关性细菌性肺炎的警示
Infect Dis Ther. 2020 Sep;9(3):417-420. doi: 10.1007/s40121-020-00306-5. Epub 2020 May 30.
8
COVID-19 and the immune system.COVID-19 与免疫系统。
Physiol Res. 2020 Jul 16;69(3):379-388. doi: 10.33549/physiolres.934492. Epub 2020 May 29.
9
A rationale for targeting the P2X7 receptor in Coronavirus disease 19.靶向治疗 2019 冠状病毒病中 P2X7 受体的原理。
Br J Pharmacol. 2020 Nov;177(21):4990-4994. doi: 10.1111/bph.15138. Epub 2020 Jul 26.
10
Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19.新型冠状病毒肺炎的肺血管内皮细胞炎症、血栓形成和血管生成。
N Engl J Med. 2020 Jul 9;383(2):120-128. doi: 10.1056/NEJMoa2015432. Epub 2020 May 21.